Nanooncology: The future of cancer diagnosis and therapy

CA Cancer Journal for Clinicians

Volumn 63, Issue 6, 2013, Pages 395-418

  Thakor, Avnesh S ^a,b,c   Gambhir, Sanjiv S ^a,d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d STANFORD UNIVERSITY   (United States)

Author keywords

cancer; chemotherapy; gene therapy; molecular imaging; nanoparticles; photodynamic therapy; thermal therapy

Indexed keywords

ASPARAGINASE MACROGOL; CAMPTOTHECIN; CARBON NANOTUBE; CRLX 101; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETIRINOTECAN PEGOL; FERUCARBOTRAN; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; MESSENGER RNA; MIFAMURTIDE; NANOPARTICLE; PACLITAXEL; PACLITAXEL POLIGLUMEX; PLATINUM COMPLEX; POLYGLACTIN; QUANTUM DOT; SINGLE WALLED NANOTUBE; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG; VINCRISTINE SULFATE; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

ACUTE LYMPHOBLASTIC LEUKEMIA; BLADDER CANCER; BREAST CANCER; CANCER DIAGNOSIS; CANCER THERAPY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; GENE SILENCING; HUMAN; HYPERTHERMIC THERAPY; KAPOSI SARCOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MENINGITIS; METASTASIS; NANOANALYSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGICAL PROCEDURE; OSTEOSARCOMA; OVARY CANCER; PANCREAS CANCER; PHOTOACOUSTICS; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAMAN SPECTROMETRY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THERAPEUTIC INDEX; TUMOR CELL; TUMOR MICROENVIRONMENT;

CANCER; CHEMOTHERAPY; GENE THERAPY; MOLECULAR IMAGING; NANOPARTICLES; PHOTODYNAMIC THERAPY; THERMAL THERAPY;

ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; MEDICAL ONCOLOGY; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84887610699     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21199     Document Type: Review

References (225)

1. Allen TM, Cullis PR,. Drug delivery systems: entering the mainstream. Science. 2004; 303: 1818-1822. (Pubitemid 38374867)
2. Brigger I, Dubernet C, Couvreur P,. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002; 54: 631-651. (Pubitemid 35247520)
3. Jain RK,. Transport of molecules in the tumor interstitium: a review. Cancer Res. 1987; 47: 3039-3051. (Pubitemid 17082621)
4. Koo H, Huh MS, Sun IC, et al. In vivo targeted delivery of nanoparticles for theranosis. Acc Chem Res. 2011; 44: 1018-1028.
5. Maeda H,. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001; 41: 189-207.
6. Niederhuber JE,. Developmental biology, self-renewal, and cancer. Lancet Oncol. 2007; 8: 456-457. (Pubitemid 46805907)
7. Brigati C, Noonan DM, Albini A, Benelli R,. Tumors and inflammatory infiltrates: friends or foes? Clin Exp Metastasis. 2002; 19: 247-258. (Pubitemid 34553525)
8. Pollard JW,. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004; 4: 71-78. (Pubitemid 38082155)
9. Bingle L, Brown NJ, Lewis CE,. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002; 196: 254-265. (Pubitemid 34189413)
10. Wang X, Yang L, Chen ZG, Shin DM,. Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin. 2008; 58: 97-110. (Pubitemid 351521865)
11. Ferrari M,. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005; 5: 161-171. (Pubitemid 40314948)
12. Li KC, Pandit SD, Guccione S, Bednarski MD,. Molecular imaging applications in nanomedicine. Biomed Microdevices. 2004; 6: 113-116. (Pubitemid 38801851)
13. Win KY, Feng SS,. In vitro and in vivo studies on vitamin E TPGS-emulsified poly(D,L-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation. Biomaterials. 2006; 27: 2285-2291. (Pubitemid 41774539)
14. Blanco NG, Maldonado CR, Mareque-Rivas JC,. Effective photoreduction of a Pt(IV) complex with quantum dots: a feasible new light-induced method of releasing anticancer Pt(II) drugs. Chem Commun (Camb). 2009;(35): 5257-5259.
15. Sapra P, Tyagi P, Allen TM,. Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv. 2005; 2: 369-381. (Pubitemid 41277769)
16. Papahadjopoulos D, Gabizon A,. Liposomes designed to avoid the reticuloendothelial system. Prog Clin Biol Res. 1990; 343: 85-93.
17. Simoes S, Filipe A, Faneca H, et al. Cationic liposomes for gene delivery. Expert Opin Drug Deliv. 2005; 2: 237-254. (Pubitemid 41135785)
18. Mamot C, Ritschard R, Wicki A, et al. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. Lancet Oncol. 2012; 13: 1234-1241.
19. Montanari M, Fabbri F, Rondini E, et al. Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer. Tumori. 2012; 98: 696-701.
20. Kaspers GJ, Zimmermann M, Reinhardt D, et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. J Clin Oncol. 2013; 31: 599-607.
21. Amadori D, Milandri C, Comella G, et al. A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer. Eur J Cancer. 2011; 47: 2091-2098.
22. Jain RK, Stylianopoulos T,. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010; 7: 653-664.
23. Stylianopoulos T, Wong C, Bawendi MG, Jain RK, Fukumura D,. Multistage nanoparticles for improved delivery into tumor tissue. Methods Enzymol. 2012; 508: 109-130.
24. Montero AJ, Adams B, Diaz-Montero CM, Gluck S,. Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review. Expert Rev Clin Pharmacol. 2011; 4: 329-334.
25. Barenholz Y,. Doxil(R)-the first FDA-approved nano-drug: lessons learned. J Control Release. 2012; 160: 117-134.
26. Petre CE, Dittmer DP,. Liposomal daunorubicin as treatment for Kaposi's sarcoma. Int J Nanomedicine. 2007; 2: 277-288. (Pubitemid 350047773)
27. Kaposi's sarcoma: DaunoXome approved. AIDS Treat News. 1996;(246): 3-4.
28. Lao J, Madani J, Puertolas T, et al. Liposomal doxorubicin in the treatment of breast cancer patients: a review. J Drug Deliv. 2013; 2013: 456409.
29. Angst MS, Drover DR,. Pharmacology of drugs formulated with DepoFoam: a sustained release drug delivery system for parenteral administration using multivesicular liposome technology. Clin Pharmacokinet. 2006; 45: 1153-1176. (Pubitemid 44904820)
30. FDA approves liposomal vincristine (Marqibo) for rare leukemia. Oncology (Williston Park). 2012; 26: 841.
31. Silverman JA, Deitcher SR,. Marqibo(R) (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother Pharmacol. 2013; 71: 555-564.
32. Dinndorf PA, Gootenberg J, Cohen MH, Keegan P, Pazdur R,. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist. 2007; 12: 991-998. (Pubitemid 47359142)
33. Okusaka T, Okada S, Ueno H, et al. Transcatheter arterial embolization with zinostatin stimalamer for hepatocellular carcinoma. Oncology (Williston Park). 2002; 62: 228-233. (Pubitemid 34639056)
34. Greish K, Fang J, Inutsuka T, Nagamitsu A, Maeda H,. Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin Pharmacokinet. 2003; 42: 1089-1105. (Pubitemid 37357647)
35. Reimer P, Balzer T,. Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol. 2003; 13: 1266-1276. (Pubitemid 36790627)
36. Oerlemans C, Bult W, Bos M, Storm G, Nijsen JF, Hennink WE,. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm Res. 2010; 27: 2569-2589.
37. Rivera Gil P, Huhn D, del Mercato LL, Sasse D, Parak WJ,. Nanopharmacy: inorganic nanoscale devices as vectors and active compounds. Pharmacol Res. 2010; 62: 115-125.
38. Maier-Hauff K, Ulrich F, Nestler D, et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol. 2011; 103: 317-324.
39. O'Brien ME, Socinski MA, Popovich AY, et al. Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol. 2008; 3: 728-734.
40. Azim HA Jr, Awada A,. Clinical development of new formulations of cytotoxics in solid tumors. Curr Opin Oncol. 2012; 24: 325-331.
41. Frampton JE,. Mifamurtide: a review of its use in the treatment of osteosarcoma. Paediatr Drugs. 2010; 12: 141-153.
42. May JP, Li SD,. Hyperthermia-induced drug targeting. Expert Opin Drug Deliv. 2013; 10: 511-527.
43. Weiss GJ, Chao J, Neidhart JD, et al. First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest New Drugs. 2013; 31: 986-1000.
44. Lee JL, Ahn JH, Park SH, et al. Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum. Invest New Drugs. 2012; 30: 1984-1990.
45. Kim DW, Kim SY, Kim HK, et al. Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer. Ann Oncol. 2007; 18: 2009-2014.
46. Saif MW,. Pancreatic cancer: are we moving forward yet? Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 20th, 2007. JOP. 2007; 8: 166-176. (Pubitemid 46522744)
47. Young C, Schluep T, Hwang J, Eliasof S,. CRLX101 (formerly IT-101)-a novel nanopharmaceutical of camptothecin in clinical development. Curr Bioact Compd. 2011; 7: 8-14.
48. Hrkach J, Von Hoff D, Mukkaram Ali M, et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 2012; 4: 128ra139.
49. Johannsen M, Gneveckow U, Taymoorian K, et al. Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: results of a prospective phase I trial. Int J Hyperthermia. 2007; 23: 315-323. (Pubitemid 46860598)
50. Davis ME,. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm. 2009; 6: 659-668.
51. Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010; 464: 1067-1070.
52. Xu L, Pirollo KF, Chang EH,. Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy. J Control Release. 2001; 74: 115-128. (Pubitemid 32727614)
53. Senzer N, Nemunaitis J, Nemunaitis D, et al. Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol Ther. 2013; 21: 1096-1103.
54. Matsumura Y, Gotoh M, Muro K, et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol. 2004; 15: 517-525. (Pubitemid 38444560)
55. Gad SC, Sharp KL, Montgomery C, Payne JD, Goodrich GP,. Evaluation of the toxicity of intravenous delivery of auroshell particles (gold-silica nanoshells). Int J Toxicol. 2012; 31: 584-594.
56. Ventola CL,. The nanomedicine revolution: part 2: current and future clinical applications. P T. 2012; 37: 582-591.
57. Thakor AS, Luong R, Paulmurugan R, et al. The fate and toxicity of Raman-active silica-gold nanoparticles in mice. Sci Transl Med. 2011; 3: 79ra33.
58. Benezra M, Penate-Medina O, Zanzonico PB, et al. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J Clin Invest. 2011; 121: 2768-2780.
59. Shao J, Griffin RJ, Galanzha EI, et al. Photothermal nanodrugs: potential of TNF-gold nanospheres for cancer theranostics. Sci Rep. 2013; 3: 1293.
60. Wei A, Mehtala JG, Patri AK,. Challenges and opportunities in the advancement of nanomedicines. J Control Release. 2012; 164: 236-246.
61. Bunjes H, Drechsler M, Koch MH, Westesen K,. Incorporation of the model drug ubidecarenone into solid lipid nanoparticles. Pharm Res. 2001; 18: 287-293. (Pubitemid 32595815)
62. Pardeike J, Hommoss A, Muller RH,. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm. 2009; 366: 170-184.
63. Faraji AH, Wipf P,. Nanoparticles in cellular drug delivery. Bioorg Med Chem. 2009; 17: 2950-2962.
64. zur Muhlen A, Schwarz C, Mehnert W,. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm. 1998; 45: 149-155. (Pubitemid 28167741)
65. Wissing SA, Kayser O, Muller RH,. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004; 56: 1257-1272. (Pubitemid 38510473)
66. Rao JP, Geckeler KE,. Polymer nanoparticles: preparation techniques and size-control parameters. Prog Polym Sci. 2011; 36: 887-913.
67. Geckeler KE, Stirn J,. Polyreactions-mechanisms, taxonomy, relevance [in German]. Naturwissenschaften. 1993; 80: 487-500.
68. Sahoo SK, Panyam J, Prabha S, Labhasetwar V,. Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release. 2002; 82: 105-114. (Pubitemid 34775052)
69. Dong Y, Feng SS,. Poly(d,l-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs. Biomaterials. 2005; 26: 6068-6076. (Pubitemid 40805612)
70. Liu Y, Pan J, Feng SS,. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance. Int J Pharm. 2010; 395: 243-250.
71. Roy I, Mitra S, Maitra A, Mozumdar S,. Calcium phosphate nanoparticles as novel non-viral vectors for targeted gene delivery. Int J Pharm. 2003; 250: 25-33. (Pubitemid 35447934)
72. Botterhuis NE, Sun Q, Magusin PC, van Santen RA, Sommerdijk NA,. Hollow silica spheres with an ordered pore structure and their application in controlled release studies. Chemistry. 2006; 12: 1448-1456. (Pubitemid 43200396)
73. Lai CY, Trewyn BG, Jeftinija DM, et al. A mesoporous silica nanosphere-based carrier system with chemically removable CdS nanoparticle caps for stimuli-responsive controlled release of neurotransmitters and drug molecules. J Am Chem Soc. 2003; 125: 4451-4459. (Pubitemid 36418692)
74. Giri S, Trewyn BG, Stellmaker MP, Lin VS,. Stimuli-responsive controlled-release delivery system based on mesoporous silica nanorods capped with magnetic nanoparticles. Angew Chem Int Ed Engl. 2005; 44: 5038-5044. (Pubitemid 41188539)
75. Radu DR, Lai CY, Jeftinija K, Rowe EW, Jeftinija S, Lin VS,. A polyamidoamine dendrimer-capped mesoporous silica nanosphere-based gene transfection reagent. J Am Chem Soc. 2004; 126: 13216-13217. (Pubitemid 39382736)
76. Zhao Y, Vivero-Escoto JL, Slowing II, Trewyn BG, Lin VS,. Capped mesoporous silica nanoparticles as stimuli-responsive controlled release systems for intracellular drug/gene delivery. Expert Opin Drug Deliv. 2010; 7: 1013-1029.
77. Choi HS, Liu W, Liu F, et al. Design considerations for tumour-targeted nanoparticles. Nat Nanotechnol. 2010; 5: 42-47.
78. Bazile D, Prud'homme C, Bassoullet MT, Marlard M, Spenlehauer G, Veillard M,. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J Pharm Sci. 1995; 84: 493-498.
79. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WC,. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 2009; 9: 1909-1915.
80. Netti PA, Roberge S, Boucher Y, Baxter LT, Jain RK,. Effect of transvascular fluid exchange on pressure-flow relationship in tumors: a proposed mechanism for tumor blood flow heterogeneity. Microvasc Res. 1996; 52: 27-46. (Pubitemid 26245691)
81. Pan D, Lanza GM, Wickline SA, Caruthers SD,. Nanomedicine: perspective and promises with ligand-directed molecular imaging. Eur J Radiol. 2009; 70: 274-285.
82. Ryu JH, Koo H, Sun IC, et al. Tumor-targeting multi-functional nanoparticles for theragnosis: new paradigm for cancer therapy. Adv Drug Deliv Rev. 2012; 64: 1447-1458.
83. De Jong WH, Borm PJ,. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine. 2008; 3: 133-149. (Pubitemid 352042401)
84. Stella B, Arpicco S, Peracchia MT, et al. Design of folic acid-conjugated nanoparticles for drug targeting. J Pharm Sci. 2000; 89: 1452-1464.
85. Miele E, Spinelli GP, Miele E, et al. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomedicine. 2012; 7: 3637-3657.
86. Tong R, Hemmati HD, Langer R, Kohane DS,. Photoswitchable nanoparticles for triggered tissue penetration and drug delivery. J Am Chem Soc. 2012; 134: 8848-8855.
87. Wu XL, Kim JH, Koo H, et al. Tumor-targeting peptide conjugated pH-responsive micelles as a potential drug carrier for cancer therapy. Bioconjug Chem. 2010; 21: 208-213.
88. Colson YL, Grinstaff MW,. Biologically responsive polymeric nanoparticles for drug delivery. Adv Mater. 2012; 24: 3878-3886.
89. Wong C, Stylianopoulos T, Cui J, et al. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci U S A. 2011; 108: 2426-2431.
90. Kauppila S, Stenback F, Risteli J, Jukkola A, Risteli L,. Aberrant type I and type III collagen gene expression in human breast cancer in vivo. J Pathol. 1998; 186: 262-268. (Pubitemid 28494353)
91. Brown E, McKee T, diTomaso E, et al. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med. 2003; 9: 796-800. (Pubitemid 36749232)
92. Timko BP, Dvir T, Kohane DS,. Remotely triggerable drug delivery systems. Adv Mater. 2010; 22: 4925-4943.
93. Nativo P, Prior IA, Brust M,. Uptake and intracellular fate of surface-modified gold nanoparticles. ACS Nano. 2008; 2: 1639-1644.
94. de la Fuente JM, Berry CC,. Tat peptide as an efficient molecule to translocate gold nanoparticles into the cell nucleus. Bioconjug Chem. 2005; 16: 1176-1180. (Pubitemid 41368118)
95. Kumar S, Harrison N, Richards-Kortum R, Sokolov K,. Plasmonic nanosensors for imaging intracellular biomarkers in live cells. Nano Lett. 2007; 7: 1338-1343. (Pubitemid 46834419)
96. Pujals S, Bastus NG, Pereiro E, et al. Shuttling gold nanoparticles into tumoral cells with an amphipathic proline-rich peptide. Chembiochem. 2009; 10: 1025-1031.
97. Panyam J, Labhasetwar V,. Targeting intracellular targets. Curr Drug Deliv. 2004; 1: 235-247.
98. Larsen AK, Escargueil AE, Skladanowski A,. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther. 2000; 85: 217-229. (Pubitemid 30160791)
99. Saito G, Swanson JA, Lee KD,. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev. 2003; 55: 199-215. (Pubitemid 36135916)
100. Panchapakesan B, Book-Newell B, Sethu P, Rao M, Irudayaraj J,. Gold nanoprobes for theranostics. Nanomedicine (Lond). 2011; 6: 1787-1811.
101. Chatterjee DK, Fong LS, Zhang Y,. Nanoparticles in photodynamic therapy: an emerging paradigm. Adv Drug Deliv Rev. 2008; 60: 1627-1637.
102. Foote CS,. Definition of type I and type II photosensitized oxidation. Photochem Photobiol. 1991; 54: 659.
103. Hatz S, Lambert JD, Ogilby PR,. Measuring the lifetime of singlet oxygen in a single cell: addressing the issue of cell viability. Photochem Photobiol Sci. 2007; 6: 1106-1116. (Pubitemid 47525006)
104. Lee Y, Baron ED,. Photodynamic therapy: current evidence and applications in dermatology. Semin Cutan Med Surg. 2011; 30: 199-209.
105. Yavari N, Andersson-Engels S, Segersten U, Malmstrom PU,. An overview on preclinical and clinical experiences with photodynamic therapy for bladder cancer. Can J Urol. 2011; 18: 5778-5786.
106. Moore CM, Emberton M, Bown SG,. Photodynamic therapy for prostate cancer-an emerging approach for organ-confined disease. Lasers Surg Med. 2011; 43: 768-775.
107. Allison R, Moghissi K, Downie G, Dixon K,. Photodynamic therapy (PDT) for lung cancer. Photodiagnosis Photodyn Ther. 2011; 8: 231-239.
108. Wang KK, Kim JY,. Photodynamic therapy in Barrett's esophagus. Gastrointest Endosc Clin N Am. 2003; 13: 483-489, vii. (Pubitemid 37071630)
109. Fan BG, Andren-Sandberg A,. Photodynamic therapy for pancreatic cancer. Pancreas. 2007; 34: 385-389. (Pubitemid 46725777)
110. Wang JB, Liu LX,. Use of photodynamic therapy in malignant lesions of stomach, bile duct, pancreas, colon and rectum. Hepatogastroenterology. 2007; 54: 718-724.
111. Quon H, Grossman CE, Finlay JC, et al. Photodynamic therapy in the management of pre-malignant head and neck mucosal dysplasia and microinvasive carcinoma. Photodiagnosis Photodyn Ther. 2011; 8: 75-85.
112. Konan-Kouakou YN, Boch R, Gurny R, Allemann E,. In vitro and in vivo activities of verteporfin-loaded nanoparticles. J Control Release. 2005; 103: 83-91. (Pubitemid 40248563)
113. Bhawalkar JD, Kumar ND, Zhao CF, Prasad PN,. Two-photon photodynamic therapy. J Clin Laser Med Surg. 1997; 15: 201-204. (Pubitemid 27518371)
114. Kim S, Ohulchanskyy TY, Pudavar HE, Pandey RK, Prasad PN,. Organically modified silica nanoparticles co-encapsulating photosensitizing drug and aggregation-enhanced two-photon absorbing fluorescent dye aggregates for two-photon photodynamic therapy. J Am Chem Soc. 2007; 129: 2669-2675. (Pubitemid 46364075)
115. Samia AC, Chen X, Burda C,. Semiconductor quantum dots for photodynamic therapy. J Am Chem Soc. 2003; 125: 15736-15737. (Pubitemid 37553678)
116. Whitehead KA, Langer R, Anderson DG,. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov. 2009; 8: 129-138.
117. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC,. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998; 391: 806-811. (Pubitemid 28099681)
118. Ameres SL, Martinez J, Schroeder R,. Molecular basis for target RNA recognition and cleavage by human RISC. Cell. 2007; 130: 101-112. (Pubitemid 47031315)
119. Chen SH, Zhaori G,. Potential clinical applications of siRNA technique: benefits and limitations. Eur J Clin Invest. 2011; 41: 221-232.
120. Masiero M, Nardo G, Indraccolo S, Favaro E,. RNA interference: implications for cancer treatment. Mol Aspects Med. 2007; 28: 143-166.
121. Oliveira S, van Rooy I, Kranenburg O, Storm G, Schiffelers RM,. Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes. Int J Pharm. 2007; 331: 211-214. (Pubitemid 46216677)
122. Chan JM, Zhang L, Tong R, et al. Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc Natl Acad Sci U S A. 2010; 107: 2213-2218.
123. Chirila TV, Rakoczy PE, Garrett KL, Lou X, Constable IJ,. The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides. Biomaterials. 2002; 23: 321-342. (Pubitemid 33051022)
124. Moghimi SM, Hunter AC, Murray JC,. Nanomedicine: current status and future prospects. FASEB J. 2005; 19: 311-330. (Pubitemid 40316520)
125. Oishi M, Nakaogami J, Ishii T, Nagasaki Y,. Smart PEGylated gold nanoparticles for the cytoplasmic delivery of siRNA to induce enhanced gene silencing. Chem Lett. 2006; 35: 1046-1047. (Pubitemid 44859908)
126. Alexis F, Pridgen EM, Langer R, Farokhzad OC,. Nanoparticle technologies for cancer therapy. Handb Exp Pharmacol. 2010;(197): 55-86.
127. Hildebrandt B, Wust P, Ahlers O, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol. 2002; 43: 33-56. (Pubitemid 34722786)
128. Huang X, Jain PK, El-Sayed IH, El-Sayed MA,. Plasmonic photothermal therapy (PPTT) using gold nanoparticles. Lasers Med Sci. 2008; 23: 217-228.
129. vaasand LO, Gomer CJ, Morinelli E,. On the physical rationale of laser induced hyperthermia. Lasers Med Sci. 1990; 5: 121-128.
130. Jain PK, Huang X, El-Sayed IH, El-Sayed MA,. Noble metals on the nanoscale: optical and photothermal properties and some applications in imaging, sensing, biology, and medicine. Acc Chem Res. 2008; 41: 1578-1586.
131. Young JK, Figueroa ER, Drezek RA,. Tunable nanostructures as photothermal theranostic agents. Ann Biomed Eng. 2012; 40: 438-459.
132. Du H, Fuh R-CA, Li J, Corkan LA, Lindsey JS,. PhotochemCAD: a computer-aided design and research tool in photochemistry. Photochem Photobiol. 1998; 68: 141-142. (Pubitemid 128472001)
133. Link S, El-Sayed MA,. Optical properties and ultrafast dynamics of metallic nanocrystals. Annu Rev Phys Chem. 2003; 54: 331-366.
134. Zharov VP, Galitovskaya EN, Johnson C, Kelly T,. Synergistic enhancement of selective nanophotothermolysis with gold nanoclusters: potential for cancer therapy. Lasers Surg Med. 2005; 37: 219-226. (Pubitemid 41464823)
135. Huang X, Jain PK, El-Sayed IH, El-Sayed MA,. Determination of the minimum temperature required for selective photothermal destruction of cancer cells with the use of immunotargeted gold nanoparticles. Photochem Photobiol. 2006; 82: 412-417.
136. Johannsen M, Gneveckow U, Thiesen B, et al. Thermotherapy of prostate cancer using magnetic nanoparticles: feasibility, imaging, and three-dimensional temperature distribution. Eur Urol. 2007; 52: 1653-1661.
137. Jordan A, Wust P, Fahling H, John W, Hinz A, Felix R,. Inductive heating of ferrimagnetic particles and magnetic fluids: physical evaluation of their potential for hyperthermia. 1993. Int J Hyperthermia. 2009; 25: 499-511.
138. Johannsen M, Jordan A, Scholz R, et al. Evaluation of magnetic fluid hyperthermia in a standard rat model of prostate cancer. J Endourol. 2004; 18: 495-500. (Pubitemid 38879152)
139. Jordan A, Scholz R, Maier-Hauff K, et al. The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. J Neurooncol. 2006; 78: 7-14. (Pubitemid 43786652)
140. Jordan A, Scholz R, Wust P, et al. Effects of magnetic fluid hyperthermia (MFH) on C3H mammary carcinoma in vivo. Int J Hyperthermia. 1997; 13: 587-605. (Pubitemid 27496845)
141. Siegmund KD, Marjoram P, Woo YJ, Tavare S, Shibata D,. Inferring clonal expansion and cancer stem cell dynamics from DNA methylation patterns in colorectal cancers. Proc Natl Acad Sci U S A. 2009; 106: 4828-4833.
142. Wang YX,. Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application. Quant Imaging Med Surg. 2011; 1: 35-40.
143. Shilo M, Reuveni T, Motiei M, Popovtzer R,. Nanoparticles as computed tomography contrast agents: current status and future perspectives. Nanomedicine (Lond). 2012; 7: 257-269.
144. de la Zerda A, Bodapati S, Teed R, et al. Family of enhanced photoacoustic imaging agents for high-sensitivity and multiplexing studies in living mice. ACS Nano. 2012; 6: 4694-4701.
145. Hong S, Leroueil PR, Majoros IJ, Orr BG, Baker JR Jr, Banaszak Holl MM,. The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem Biol. 2007; 14: 107-115. (Pubitemid 46124068)
146. Hirn S, Semmler-Behnke M, Schleh C, et al. Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration. Eur J Pharm Biopharm. 2011; 77: 407-416.
147. Decuzzi P, Godin B, Tanaka T, et al. Size and shape effects in the biodistribution of intravascularly injected particles. J Control Release. 2010; 141: 320-327.
148. Gratton SE, Ropp PA, Pohlhaus PD, et al. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A. 2008; 105: 11613-11618.
149. Wang S, Lu W, Tomvmachenko O, Rai US, Yu H, Ray PC,. Challenge in understanding the size and shape dependent toxicity of gold nanomaterial in human skin keratinocytes. Chem Phys Lett. 2008; 463: 145-149.
150. Sun YN, Wang CD, Zhang XM, Ren L, Tian XH,. Shape dependence of gold nanoparticles on in vivo acute toxicological effects and biodistribution. J Nanosci Nanotechnol. 2011; 11: 1210-1216.
151. Nie Z, Petukhova A, Kumacheva E,. Properties and emerging applications of self-assembled structures made from inorganic nanoparticles. Nat Nanotechnol. 2010; 5: 15-25.
152. von Maltzahn G, Harris TJ, Park JH, et al. Nanoparticle self-assembly gated by logical proteolytic triggers. J Am Chem Soc. 2007; 129: 6064-6065. (Pubitemid 46786782)
153. Liang G, Ren H, Rao J,. A biocompatible condensation reaction for controlled assembly of nanostructures in living cells. Nat Chem. 2010; 2: 54-60.
154. Frey NA, Peng S, Cheng K, Sun S,. Magnetic nanoparticles: synthesis, functionalization, and applications in bioimaging and magnetic energy storage. Chem Soc Rev. 2009; 38: 2532-2542.
155. Ananta JS, Godin B, Sethi R, et al. Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast. Nat Nanotechnol. 2010; 5: 815-821.
156. Weissleder R, Stark DD, Engelstad BL, et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am J Roentgenol. 1989; 152: 167-173. (Pubitemid 19024086)
157. Lee PW, Hsu SH, Wang JJ, et al. The characteristics, biodistribution, magnetic resonance imaging and biodegradability of superparamagnetic core-shell nanoparticles. Biomaterials. 2010; 31: 1316-1324.
158. Tanimoto A, Kuribayashi S,. Application of superparamagnetic iron oxide to imaging of hepatocellular carcinoma. Eur J Radiol. 2006; 58: 200-216.
159. Rosen JE, Chan L, Shieh DB, Gu FX,. Iron oxide nanoparticles for targeted cancer imaging and diagnostics. Nanomedicine. 2012; 8: 275-290.
160. Sonvico F, Mornet S, Vasseur S, et al. Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential specific magnetic hyperthermia mediators: synthesis, physicochemical characterization, and in vitro experiments. Bioconjug Chem. 2005; 16: 1181-1188. (Pubitemid 41368119)
161. Choi H, Choi SR, Zhou R, Kung HF, Chen IW,. Iron oxide nanoparticles as magnetic resonance contrast agent for tumor imaging via folate receptor-targeted delivery. Acad Radiol. 2004; 11: 996-1004. (Pubitemid 39220809)
162. Sun C, Sze R, Zhang M,. Folic acid-PEG conjugated superparamagnetic nanoparticles for targeted cellular uptake and detection by MRI. J Biomed Mater Res A. 2006; 78: 550-557. (Pubitemid 44253539)
163. Kresse M, Wagner S, Pfefferer D, Lawaczeck R, Elste V, Semmler W,. Targeting of ultrasmall superparamagnetic iron oxide (USPIO) particles to tumor cells in vivo by using transferrin receptor pathways. Magn Reson Med. 1998; 40: 236-242. (Pubitemid 28361526)
164. Li H, Qian ZM,. Transferrin/transferrin receptor-mediated drug delivery. Med Res Rev. 2002; 22: 225-250. (Pubitemid 34415465)
165. Zhang C, Jugold M, Woenne EC, et al. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res. 2007; 67: 1555-1562. (Pubitemid 46383379)
166. Brooks PC, Clark RA, Cheresh DA,. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994; 264: 569-571.
167. Remsen LG, McCormick CI, Roman-Goldstein S, et al. MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive diagnosis. AJNR Am J Neuroradiol. 1996; 17: 411-418. (Pubitemid 26101942)
168. Suwa T, Ozawa S, Ueda M, Ando N, Kitajima M,. Magnetic resonance imaging of esophageal squamous cell carcinoma using magnetite particles coated with anti-epidermal growth factor receptor antibody. Int J Cancer. 1998; 75: 626-634. (Pubitemid 28094112)
169. Toma A, Otsuji E, Kuriu Y, et al. Monoclonal antibody A7-superparamagnetic iron oxide as contrast agent of MR imaging of rectal carcinoma. Br J Cancer. 2005; 93: 131-136. (Pubitemid 41076261)
170. Wang AZ, Bagalkot V, Vasilliou CC, et al. Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem. 2008; 3: 1311-1315.
171. Wong RM, Gilbert DA, Liu K, Louie AY,. Rapid size-controlled synthesis of dextran-coated, 64Cu-doped iron oxide nanoparticles. ACS Nano. 2012; 6: 3461-3467.
172. Lee S, Kim S, Choo J, et al. Biological imaging of HEK293 cells expressing PLCgamma1 using surface-enhanced Raman microscopy. Anal Chem. 2007; 79: 916-922.
173. Keren S, Zavaleta C, Cheng Z, de la Zerda A, Gheysens O, Gambhir SS,. Noninvasive molecular imaging of small living subjects using Raman spectroscopy. Proc Natl Acad Sci U S A. 2008; 105: 5844-5849. (Pubitemid 351758460)
174. Chan WC, Nie S,. Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science. 1998; 281: 2016-2018. (Pubitemid 28475486)
175. Walling MA, Novak JA, Shepard JR,. Quantum dots for live cell and in vivo imaging. Int J Mol Sci. 2009; 10: 441-491.
176. Gao X, Cui Y, Levenson RM, Chung LW, Nie S,. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol. 2004; 22: 969-976. (Pubitemid 39014473)
177. Ruan Y, Yu W, Cheng F, et al. Comparison of quantum-dots- and fluorescein-isothiocyanate-based technology for detecting prostate-specific antigen expression in human prostate cancer. IET Nanobiotechnol. 2011; 5: 47.
178. Yang K, Zhang FJ, Tang H, et al. In-vivo imaging of oral squamous cell carcinoma by EGFR monoclonal antibody conjugated near-infrared quantum dots in mice. Int J Nanomedicine. 2011; 6: 1739-1745.
179. Chen H, Li L, Cui S, Mahounga D, Zhang J, Gu Y,. Folate conjugated CdHgTe quantum dots with high targeting affinity and sensitivity for in vivo early tumor diagnosis. J Fluoresc. 2011; 21: 793-801.
180. Yong KT, Roy I, Law WC, Hu R,. Synthesis of cRGD-peptide conjugated near-infrared CdTe/ZnSe core-shell quantum dots for in vivo cancer targeting and imaging. Chem Commun (Camb). 2010; 46: 7136-7138.
181. Cai W, Chen K, Li ZB, Gambhir SS, Chen X,. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J Nucl Med. 2007; 48: 1862-1870. (Pubitemid 350099333)
182. Banholzer MJ, Millstone JE, Qin L, Mirkin CA,. Rationally designed nanostructures for surface-enhanced Raman spectroscopy. Chem Soc Rev. 2008; 37: 885-897.
183. Zavaleta CL, Smith BR, Walton I, et al. Multiplexed imaging of surface enhanced Raman scattering nanotags in living mice using noninvasive Raman spectroscopy. Proc Natl Acad Sci U S A. 2009; 106: 13511-13516.
184. Kircher MF, de la Zerda A, Jokerst JV, et al. A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Nat Med. 2012; 18: 829-834.
185. Wang X, Pang Y, Ku G, Xie X, Stoica G, Wang LV,. Noninvasive laser-induced photoacoustic tomography for structural and functional in vivo imaging of the brain. Nat Biotechnol. 2003; 21: 803-806. (Pubitemid 36791400)
186. Pan D, Cai X, Yalaz C, et al. Photoacoustic sentinel lymph node imaging with self-assembled copper neodecanoate nanoparticles. ACS Nano. 2012; 6: 1260-1267.
187. de la Zerda A, Kim JW, Galanzha EI, Gambhir SS, Zharov VP,. Advanced contrast nanoagents for photoacoustic molecular imaging, cytometry, blood test and photothermal theranostics. Contrast Media Mol Imaging. 2011; 6: 346-369.
188. Manohar S, Ungureanu C, Van Leeuwen TG,. Gold nanorods as molecular contrast agents in photoacoustic imaging: the promises and the caveats. Contrast Media Mol Imaging. 2011; 6: 389-400.
189. Jokerst JV, Thangaraj M, Kempen PJ, Sinclair R, Gambhir SS,. Photoacoustic imaging of mesenchymal stem cells in living mice via silica-coated gold nanorods. ACS Nano. 2012; 6: 5920-5930.
190. De la Zerda A, Zavaleta C, Keren S, et al. Carbon nanotubes as photoacoustic molecular imaging agents in living mice. Nat Nanotechnol. 2008; 3: 557-562.
191. Pan D, Pramanik M, Senpan A, et al. Molecular photoacoustic tomography with colloidal nanobeacons. Angew Chem Int Ed Engl. 2009; 48: 4170-4173.
192. Li PC, Wei CW, Liao CK, et al. Photoacoustic imaging of multiple targets using gold nanorods. IEEE Trans Ultrason Ferroelectr Freq Control. 2007; 54: 1642-1647.
193. Pan D, Pramanik M, Senpan A, et al. Near infrared photoacoustic detection of sentinel lymph nodes with gold nanobeacons. Biomaterials. 2010; 31: 4088-4093.
194. Liu Z, Cai W, He L, et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol. 2007; 2: 47-52. (Pubitemid 46210038)
195. Adriani G, de Tullio MD, Ferrari M, et al. The preferential targeting of the diseased microvasculature by disk-like particles. Biomaterials. 2012; 33: 5504-5513.
196. Ahmed N, Fessi H, Elaissari A,. Theranostic applications of nanoparticles in cancer. Drug Discov Today. 2012; 17: 928-934.
197. Sumer B, Gao J,. Theranostic nanomedicine for cancer. Nanomedicine (Lond). 2008; 3: 137-140. (Pubitemid 351611851)
198. Kohler N, Sun C, Wang J, Zhang M,. Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells. Langmuir. 2005; 21: 8858-8864. (Pubitemid 41396647)
199. Chopra A,. Trastuzumab-dextran iron oxide nanoparticles. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information; 2004.
200. Ling Y, Wei K, Zou F, Zhong S,. Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma. Int J Pharm. 2012; 430: 266-275.
201. Hu SH, Liao BJ, Chiang CS, Chen PJ, Chen IW, Chen SY,. Core-shell nanocapsules stabilized by single-component polymer and nanoparticles for magneto-chemotherapy/hyperthermia with multiple drugs. Adv Mater. 2012; 24: 3627-3632.
202. Cheng K, Peng S, Xu C, Sun S,. Porous hollow Fe(3)O(4) nanoparticles for targeted delivery and controlled release of cisplatin. J Am Chem Soc. 2009; 131: 10637-10644.
203. Lee HJ, Nguyen YT, Muthiah M, et al. MR traceable delivery of p53 tumor suppressor gene by PEI-functionalized superparamagnetic iron oxide nanoparticles. J Biomed Nanotechnol. 2012; 8: 361-371.
204. Wang H, Wang S, Liao Z, et al. Folate-targeting magnetic core-shell nanocarriers for selective drug release and imaging. Int J Pharm. 2012; 430: 342-349.
205. Castillo B, Bromberg L, Lopez X, et al. Intracellular delivery of siRNA by polycationic superparamagnetic nanoparticles. J Drug Deliv 2012; 2012: 218940.
206. Yang X, Hong H, Grailer JJ, et al. cRGD-functionalized, DOX-conjugated, and (6)(4)Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials. 2011; 32: 4151-4160.
207. Fabbro C, Ali-Boucetta H, Da Ros T, Kostarelos K, Bianco A, Prato M,. Targeting carbon nanotubes against cancer. Chem Commun (Camb). 2012; 48: 3911-3926.
208. Huang N, Wang H, Zhao J, Lui H, Korbelik M, Zeng H,. Single-wall carbon nanotubes assisted photothermal cancer therapy: animal study with a murine model of squamous cell carcinoma. Lasers Surg Med. 2010; 42: 638-648.
209. Kam NW, Liu Z, Dai H,. Carbon nanotubes as intracellular transporters for proteins and DNA: an investigation of the uptake mechanism and pathway. Angew Chem Int Ed Engl. 2006; 45: 577-581. (Pubitemid 43121447)
210. Liu Z, Sun X, Nakayama-Ratchford N, Dai H,. Supramolecular chemistry on water-soluble carbon nanotubes for drug loading and delivery. ACS Nano. 2007; 1: 50-56.
211. Samori C, Ali-Boucetta H, Sainz R, et al. Enhanced anticancer activity of multi-walled carbon nanotube-methotrexate conjugates using cleavable linkers. Chem Commun (Camb). 2010; 46: 1494-1496.
212. Liu Z, Chen K, Davis C, et al. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res. 2008; 68: 6652-6660.
213. Harper BW, Krause-Heuer AM, Grant MP, Manohar M, Garbutcheon-Singh KB, Aldrich-Wright JR,. Advances in platinum chemotherapeutics. Chemistry. 2010; 16: 7064-7077.
214. Arsawang U, Saengsawang O, Rungrotmongkol T, et al. How do carbon nanotubes serve as carriers for gemcitabine transport in a drug delivery system? J Mol Graph Model. 2011; 29: 591-596.
215. Villa CH, Dao T, Ahearn I, et al. Single-walled carbon nanotubes deliver peptide antigen into dendritic cells and enhance IgG responses to tumor-associated antigens. ACS Nano. 2011; 5: 5300-5311.
216. Zhang Z, Yang X, Zhang Y, et al. Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Clin Cancer Res. 2006; 12: 4933-4939. (Pubitemid 44338581)
217. Glazer ES, Zhu C, Massey KL, et al. Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles. Clin Cancer Res. 2010; 16: 5712-5721.
218. Dong W, Li Y, Niu D, et al. Facile synthesis of monodisperse superparamagnetic Fe3O4 Core@hybrid@Au shell nanocomposite for bimodal imaging and photothermal therapy. Adv Mater. 2011; 23: 5392-5397.
219. Ke H, Wang J, Dai Z, et al. Gold-nanoshelled microcapsules: a theranostic agent for ultrasound contrast imaging and photothermal therapy. Angew Chem Int Ed Engl. 2011; 50: 3017-3021.
220. Huang P, Bao L, Zhang C, et al. Folic acid-conjugated silica-modified gold nanorods for X-ray/CT imaging-guided dual-mode radiation and photo-thermal therapy. Biomaterials. 2011; 32: 9796-9809.
221. Jia X, Jia L,. Nanoparticles improve biological functions of phthalocyanine photosensitizers used for photodynamic therapy. Curr Drug Metab. 2012; 13: 1119-1122.
222. Kuo WS, Chang YT, Cho KC, et al. Gold nanomaterials conjugated with indocyanine green for dual-modality photodynamic and photothermal therapy. Biomaterials. 2012; 33: 3270-3278.
223. Brandenberger C, Rothen-Rutishauser B, Muhlfeld C, et al. Effects and uptake of gold nanoparticles deposited at the air-liquid interface of a human epithelial airway model. Toxicol Appl Pharmacol. 2010; 242: 56-65.
224. Pan Y, Leifert A, Ruau D, et al. Gold nanoparticles of diameter 1.4 nm trigger necrosis by oxidative stress and mitochondrial damage. Small. 2009; 5: 2067-2076.
225. Goodman CM, McCusker CD, Yilmaz T, Rotello VM,. Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. Bioconjug Chem. 2004; 15: 897-900. (Pubitemid 38981966)